Article Text

Download PDFPDF

Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q What are the effects of donepezil on activities of daily living, and social functioning in people with moderate to severe Alzheimer’s disease, and what are the effects on caregiver burden?


Embedded Image  Design:

Randomised controlled trial.

Embedded Image  Allocation:


Embedded Image  Blinding:

Double blind.

Embedded Image  Follow up period:

24 weeks.

Embedded Image  Setting:

32 centres in Canada (22), Australia (6) and France (4).

Embedded Image  Patients:

290 people with moderate to severe Alzheimer’s disease (assessed using National Institute of Neurological and Communicative Disorders and Strokes-Alzheimer’s Disease and Related Disorders Association criteria), with a committed caregiver, living in the community or in assisted living facilities. Participants had standardised Mini-Mental State Examination (sMMSE) scores of 5 to 17; mean age 73 years (donepezil group), and 74 years (placebo group). Exclusions: requiring 24 hour skilled nursing care; confinement to wheelchair; and taking medications with cholinomimetic or …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.